Biologics and Biosimilar Patent Litigation Industry? Large molecule products are playing an ever-increasing role in the product portfolio of pharmaceutical and biotech companies. By consequence, there are numerous patent litigation challenges that arise from novel and complex drug formulations. This expert and industry-led panel session will highlight these issues and enable you to have comprehensive outlook on the state of pharma and biotech patent litigation. • Discuss the interplay between regulatory exclusivity and biosimilar litigation. • Understand the significance of the biosimilar battle between Johnson & Johnson and Abbvie over the product Stelara:

• Does this suggest a trend towards out of court settlements?
• Are preliminary injunctions possible?
• Will patent thickets grow? • Discuss the unique biosimilar launch considerations in Europe and the potential for large scale litigation. • Understand the key takeaways from antibody patent litigation cases:
• EPO Boards of Appeal in T 0435/20
• Biogen vs Polpharma Biologics in T 1992/21
• Furo Ventures vs Regeneron T 1589/19